Financial Performance - For the six months ended June 30, 2023, the turnover decreased by 50% to RMB 15,025,000 compared to RMB 30,299,000 for the same period in 2022[7] - Profit for the period was RMB 5,826,000, down from RMB 16,250,000 in the previous year, representing a decline of approximately 64%[3] - Basic and diluted earnings per share decreased to 0.6 cents from 1.63 cents in the prior year[3] Assets and Liabilities - Total assets less current liabilities increased to RMB 147,709,000 as of June 30, 2023, compared to RMB 141,883,000 at the end of 2022[4] - Cash and cash equivalents at the end of the period were RMB 4,534,000, up from RMB 4,060,000 at the beginning of the period[5] - Trade payables increased to RMB 20,534,000 as of June 30, 2023, from RMB 13,574,000 at the end of 2022[4] - The company has a net current assets position of RMB 145,549,000, slightly up from RMB 140,484,000 at the end of 2022[4] Operating Activities - The company reported net cash generated from operating activities of RMB 1,164,000, compared to RMB 716,000 in the same period last year[5] Business Operations - The company is engaged in providing research, development, and medical science events, with no revenue from related parties during the period[7] - The company’s subsidiaries are subject to a preferential tax rate of 15%[8] Corporate Governance - The board consists of two executive directors, one non-executive director, and four independent non-executive directors[12] Announcement and Compliance - The announcement confirms that the information provided is accurate and complete in all material aspects[12] - The announcement will be published on the GEM website for seven days from the date of release[12]
中国医疗集团(08225) - 2023 - 中期财报